A Systems medicine approach to chronic inflammatory disease

Project: Research

Project Details


The SYSCID consortium aims to develop a systems medicine approach for disease prediction in CID. We will focus on three major CID indications with distinct characteristics, yet a large overlap of their molecular risk map: inflammatory bowel disease, systemic lupus erythematodes and rheumatoid arthritis. We have joined 15 partners from major cohorts and initiatives in Europe (e.g.IHEC, ICGC, TwinsUK and Meta-HIT) to investigate human data sets on three major levels of resolution: whole blood signatures, signatures from purified immune cell types (with a focus on CD14 and CD4/CD8) and selected single cell level analyses. Principle data layers will comprise SNP variome, methylome, transcriptome and gut microbiome. SYSCID employs a dedicated data management infrastructure, strong algorithmic development groups (including an SME for exploitation of innovative software tools for data deconvolution) and will validate results in independent retrospective and prospective clinical cohorts.
Using this setup we will focus on three fundamental aims : (i) the identification of shared and unique ""core disease signatures” which are associated with the disease state and independent of temporal variation, (ii) the generation of ""predictive models of disease outcome""- builds on previous work that pathways/biomarkers for disease outcome are distinct from initial disease risk and may be shared across diseases to guide therapy decisions on an individual patient basis, (iii) ""reprogramming disease""- will identify and target temporally stable epigenetic alterations in macrophages and lymphocytes in epigenome editing approaches as biological validation and potential novel therapeutic tool .
Thus, SYSCID will foster the development of solid biomarkers and models as stratification in future long-term systems medicine clinical trials but also investigate new causative therapies by editing the epigenome code in specific immune cells, e.g. to alleviate macrophage polarization defects.
Effective start/end date01/01/201731/03/2022

Collaborative partners

  • Christian-Albrechts-University of Kiel (Beneficiary) (lead)
  • VIB (Beneficiary)
  • University of Cambridge (Beneficiary)
  • University of Liège (Beneficiary)
  • University of Geneva (Project partner)
  • Comma Soft AG (Beneficiary)
  • University of Bonn (Beneficiary)
  • University of Luxembourg (Beneficiary)
  • Saarland University (Beneficiary)
  • Humanitas University (Beneficiary)
  • Biomedical Research Foundation of the Academy of Athens (Beneficiary)
  • Genos (Beneficiary)
  • Eurice - European Research and Project Office GmbH (Beneficiary)
  • King's College London (Beneficiary)
  • University of Southern Denmark (Beneficiary)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.